Co-diagnostics, inc. initiates clinical evaluations for its at-home and point-of-care co-dx pcr home™ platform

Salt lake city , feb. 22, 2023 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has commenced clinical evaluations for its at-home and point-of-care co-dx pcr home™ platform and initial covid-19 test, consisting of the clinical trials and analytical studies that are expected to support submissions to the united states fda and other regulatory bodies. the company's real-time pcr platform has been developed for detection of infectious diseases in at-home and point-of-care settings, with anticipated multiplex panels to follow after receipt of the platform's initial regulatory authorization.
CODX Ratings Summary
CODX Quant Ranking